Dexrazoxane Intravenous and Insulin glargine and lixisenatide Subcutaneous
Determining the interaction of Dexrazoxane Intravenous and Insulin glargine and lixisenatide Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: dexrazoxane
Brand name: Totect, Zinecard
Synonyms: Dexrazoxane
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dexrazoxane Intravenous-Insulin glargine, recombinant Subcutaneous
- Dexrazoxane Intravenous-Insulin glulisine
- Dexrazoxane Intravenous-Insulin Glulisine (Cartridges and Pens)
- Dexrazoxane Intravenous-Insulin Glulisine (Vials)
- Dexrazoxane Intravenous-Insulin glulisine Subcutaneous
- Dexrazoxane Intravenous-Insulin human inhaled Inhalation
- Insulin glargine and lixisenatide Subcutaneous-Dextenza Insert
- Insulin glargine and lixisenatide Subcutaneous-Dextenza intraocular
- Insulin glargine and lixisenatide Subcutaneous-Dextran 40
- Insulin glargine and lixisenatide Subcutaneous-Dextran 70 6% in 5% Dextrose high molecular weight
- Insulin glargine and lixisenatide Subcutaneous-Dextran 75
- Insulin glargine and lixisenatide Subcutaneous-Dextran high molecular weight